Alexion Pharma (ALXN) Tops Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Alexion Pharma (ALXN) Gains Amid Conference Call
January 29, 2015 10:29 AM ESTAlexion Pharma (NASDAQ: ALXN) gained on statements made during its conference call.
It sees Q1 product revenue of $585-$590. 2015 tax rate is seen at 7%-9% vs 13%-15% prior. It expected US and EU decisions on Asfotase Alfa by mid-year, and Japan by the end of the year.
... MoreAlexion Pharma (ALXN) CEO Bell to Retire; Successor Named
January 29, 2015 6:31 AM ESTAlexion Pharma (NASDAQ: ALXN) announced that its Board of Directors has appointed David L. Hallal as the Companys Chief Executive Officer (CEO), effective April 1, 2015. Mr. Hallal currently serves as Alexions Chief Operating Officer (COO) and is a Director of the Board. He will succeed Leonard Bell, M.D., Chairman and CEO, who will retire as CEO and continue to serve as Chairman of the Board. Dr. Bell was the principal founder of Alexion in 1992 and has served as CEO for the past 23 years.
Mr. Hallal, 48, has more than 25 years of experience in the... More
